Chinese Journal of Tissue Engineering Research ›› 2026, Vol. 30 ›› Issue (1): 120-129.doi: 10.12307/2026.538

Previous Articles     Next Articles

Alpha-ketoglutarate engineered small extracellular vesicles delay skin aging

Wu Zhijing1, 2, Li Jiali1, 2, Zhang Jiaxin1, 2, Wang Tangrong1, 2, Zheng Yuzhou1, 2, Sun Zixuan1, 2   

  1. 1Department of Laboratory Medicine, Medical College of Jiangsu University, Zhenjiang 212013, Jiangsu Province, China; 2Zhenjiang Key Laboratory of High Technology Research on Exosomes Foundation and Transformation Application, Zhenjiang 212013, Jiangsu Province, China
  • Received:2024-11-15 Accepted:2025-01-21 Online:2026-01-08 Published:2025-07-02
  • Contact: Sun Zixuan, MD, Associate professor, Master’s supervisor, Department of Laboratory Medicine, Medical College of Jiangsu University, Zhenjiang 212013, Jiangsu Province, China; Zhenjiang Key Laboratory of High Technology Research on Exosomes Foundation and Transformation Application, Zhenjiang 212013, Jiangsu Province, China
  • About author:Wu Zhijing, Master candidate, Department of Laboratory Medicine, Medical College of Jiangsu University, Zhenjiang 212013, Jiangsu Province, China; Zhenjiang Key Laboratory of High Technology Research on Exosomes Foundation and Transformation Application, Zhenjiang 212013, Jiangsu Province, China
  • Supported by:
    National Natural Science Foundation of China, No. 82003379 (to SZX)

Abstract: BACKGROUND: Cell-free therapy is a research hotspot in the field of medical cosmetic anti-aging. It is still unknown for paracellular secretion of human umbilical cord mesenchymal stem cell-derived small extracellular vesicles loaded with the antiaging drug α-ketoglutaric acid to delay skin aging.
OBJECTIVE: To investigate the effect of the anti-aging agent α-ketoglutarate engineered human umbilical cord mesenchymal stem cell-derived small extracellular vesicles in a D-galactose-induced model of dermal fibroblast senescence. 
METHODS: (1) Biological characteristics of primary human umbilical cord mesenchymal stem cells were identified by osteogenic-lipogenic differentiation staining and flow cytometry. (2) The small extracellular vesicles derived from human umbilical cord mesenchymal stem cell were obtained by using differential-ultracentrifugation. α-Ketoglutarate-engineered human umbilical cord mesenchymal stem cell-small extracellular vesicles were constructed by electroporation, and biologically characterized by transmission electron microscopy and nanoparticle tracking analyzer, while the encapsulation rate was assessed using high-performance liquid chromatography. (3) The effect of α-ketoglutarate on the proliferative capacity of dermal fibroblasts was assessed by CCK-8 and Edu cell proliferation assay kits. (4) The effect of α-ketoglutarate-engineered human umbilical cord mesenchymal stem cell-small extracellular vesicles on delaying the senescence of dermal fibroblasts was evaluated by reactive oxygen species detection kit, western blot assay, and cellular immunofluorescence. 
RESULTS AND CONCLUSION: (1) The obtained human umbilical cord mesenchymal stem cell and human umbilical cord mesenchymal stem cell-small extracellular vesicles were biologically compatible. (2) There was no toxic effect on dermal fibroblasts when α-ketoglutarate was used in the concentration range of 0.5-8 mmol/L. (3) D-gal induced senescence in dermal fibroblasts, while α-ketoglutarate-engineered human umbilical cord mesenchymal stem cell-small extracellular vesicles treatment reduced the level of oxidative stress, DNA damage, and collagen loss, which was further verified that α-ketoglutarate-engineered human umbilical cord mesenchymal stem cell-small extracellular vesicles could effectively slow down the skin aging process.

Key words: ">small extracellular vesicle, human umbilical cord mesenchymal stem cell, α-ketoglutarate, senescence, dermal fibroblast, electroporation, oxidative stress, DNA damage, engineered extracellular vesicle

CLC Number: